Dermal Filler Injections: Preventing & Managing Complications | Pearls from the Expert
During the 2021 Skin of Color Update Virtual Conference, Dr. Hassan Galadari provided a highly anticipated lecture in which he discussed prevention and management of complications with dermal filler injections.
[caption id="attachment_14289" align="alignleft" width="1024"] Table 1[/caption]
The different types of dermal filers, shown above in Table 1, have been associated with a variety of c …
During the 2021 Skin of Color Update Virtual Conference, Dr. Hassan Galadari provided a highly anticipated lecture in which he discussed prevention and management of complications with dermal filler injections.
[caption id="attachment_14289" align="alignleft" width="1024"] Table 1[/caption]
The different types of dermal filers, shown above in Table 1, have been associated with a variety of c … 
A 42 year-old woman has the findings pictured, as well as erythematous patches on the upper chest and shoulders. No Raynaud's, polyarthritis, pulmonary, or cardiac involvement is noted. Which antibody might you expect to be present in this patient?
A. Anti-SRB
B. Anti-Jo-1
C. Anti-Mi-2
D. Anti-Ku
E. Anti-La
To find out the correct answer and read the explanation, click here.
… 
Rosacea is defined by facial erythema and telangiectasias, two features that are more difficult to appreciate in patients with skin of color. To refine our ability to diagnose rosacea in all skin types, on day two of the 2021 Skin of Color Update virtual conference, we had an informative, evidence-based lecture, “Recognizing, Diagnosing, and Treating Rosacea in Patients with Skin of Color,” by … 
A 25 year-old previously healthy man presents with the skin findings shown, urethritis, and one month of peripheral arthritis. Which of the following is true regarding this condition?
A. Females and males are equally affected
B. A chronic deforming arthritis occurs in 20%
C. TNF-alpha inhibiting agents have no role in the treatment of this condition
D. Patients must have urethritis … 
Hyperhidrosis affects up to 4.8% of people in the United States, causing significant impacts in patient quality of life.1 Often times, the etiology of symptoms cannot be identified, resulting in a subset of disease termed “primary hyperhidrosis.” Symptoms may be focal or generalized. Because there is a scarcity of FDA-approved treatments for primary hyperhidrosis, treatment often requires a mu … 